Betopharm and Bonray Bio Announce Strategic Collaboration to Accelerate Commercialization of Gene and Cell Therapies

SuzhouSeptember 14, 2023PR Newswire -- September 13, 2023, Porton Biologics Ltd. (referred to as Porton Biologics) announced a strategic partnership with BRL Medicine Inc. (referred to as BRL Medicine).Both parties will expand in-depth cooperation in the gene and cell therapy pipeline, rapidly advance clinical trials, and accelerate the commercialization process of innovative therapies.

Porton Biologics Ltd. and BRL Medicine Inc. Reach Strategic Cooperation to Accelerate the Commercialization of Gene and Cell Therapy Drugs

BRL Medicine, relying on profound gene editing technology, strong R&D capabilities, and forward-looking pipeline layout, has been deeply engaged in the GCT field for many years and achieved rapid development. Currently, multiple products have entered the IND application stage, and three core products have been approved for IND in China. Among them, the products are based on a self-developed hematopoietic stem cell platform (ModiHSC).^®) The gene therapy product BRL-101 developed by BRL Medicine, and the non-viral targeted integration CAR-T platform (Quikin CART^®) The CAR-T product BRL-201 developed by BRL Medicine has achieved outstanding results in clinical trials and receivedNature, Nature Medicine, etc.Recognized by multiple authoritative international academic journals. Porton Biologics Ltd. has an end-to-end CDMO service platform for gene and cell therapy, covering fields such as plasmids, cell therapy, gene therapy, oncolytic viruses, nucleic acid therapy, and live bacterial therapeutics, with extensive CMC experience in cell therapy.This strategic cooperation between the two parties will accelerate the commercialization of cell therapy drugs, allowing innovative treatments to benefit more patients.

Porton Biologics Ltd. and BRL Medicine Reach Strategic Cooperation to Accelerate the Commercialization of Gene and Cell Therapy Drugs

BRL MedicineCEO Dr. Zheng Biao stated:"We are very pleased to enter into an in-depth strategic cooperation with Porton Biologics Ltd., which has rich CDMO service experience in the international CGT field.Currently, BRL Medicine hasThere isThree new drug projects have been approved for IND in China and are currently in the phase of accelerating product launch and facing intense demand for drug production capacity. It is expected that through future diversified cooperation models, the clinical trial transformation and implementation of multiple innovative drugs from BRL Medicine will be expedited to benefit patients worldwide suffering from genetic diseases, malignant tumors, and autoimmune disorders. It is also hoped that this collaboration will further promote the prosperity and development of China's biotechnology industry.。"

Dr. Wang Yangzhou, CEO of Porton Biologics Ltd., said:"We are very pleased to reach a strategic cooperation with BRL Medicine. BRL Medicine has a strong technical platform and continuous innovation capabilities, and currently, multiple R&D pipelines have achieved gratifying results.Looking Forward to Porton Biologics Ltd.'s End-to-End Gene and Cell TherapyCDMO Platform Supports BRL Medicine in Advancing Clinical Trials and Future Commercial Production of Cell Therapy Products, Successfully Launching Safer, More Effective, and More Accessible Innovative Drugs. It is Hoped That with the Joint Efforts of Both Parties, the Development of China's CGT Field Will Be Promoted, Allowing Good Medicines to Benefit the Public Earlier."

About BRL Medicine

BRL Medicine Inc. is committed to becoming a globally leading cell and gene therapy company in the era of new commercial civilization. With the mission of "leading innovation with gene editing technology, developing breakthrough therapies, and benefiting all humanity," BRL Medicine, relying on its self-developed center and the "Shanghai Gene Editing and Cell Therapy Research Center" co-built with universities, has generated more than 100 patent achievements so far. Currently, five projects are undergoing investigator-initiated clinical trials at eight renowned hospitals, three projects have been approved for IND, officially entering the registered clinical trial phase, and several other projects are in the IND application stage. Among them, the gene-editing treatment for β-thalassemia, non-viral PD1 targeted integration CAR-T, and UCART projects have achieved excellent clinical results, demonstrating global leadership.Nature、Nature Medicine、Nature biotechnology... published multiple academic papers in well-known academic journals. BRL Medicine has established five proprietary technology platforms: a gene-editing technology innovation platform, a hematopoietic stem cell platform, a non-viral site-specific integration CAR-T platform, a universal cell platform, and an enhanced T-cell platform. It also owns a 7,000-square-meter GMP pilot production base and a nearly 200-person operations team, strongly ensuring that innovative research results can be quickly transformed and applied. BRL Medicine continuously drives the rapid iteration of its R&D products based on patient needs and clinical feedback. With an open, sharing, and win-win attitude, BRL Medicine collaborates with global innovative biopharmaceutical ecosystem companies to accelerate the translation and implementation of innovative drugs, benefiting patients worldwide who suffer from genetic diseases, malignant tumors, and autoimmune disorders!

About Porton Biologics

Porton Biologics Ltd. was established in December 2018, based in Suzhou Industrial Park, and relies on the listed company-Chongqing Porton Pharmaceutical Technology Co., Ltd. (stock code: 300363) to build CDMO platforms for plasmids, cell therapy, gene therapy, oncolytic viruses, nucleic acid therapy, and live bacterial therapies. It provides end-to-end services from library construction, process and analytical method development, cGMP production to formulation filling, covering different stages of drug development, helping customers accelerate the drug research and development and marketing process.

Porton Biologics Ltd. focuses on gene and cell therapy. Building on the successful experience of Porton Corporation, it centers around top international professional talent, adhering to the service principle of "Customer First" and the brand philosophy of "Compliance, Professionalism, Dedication, and Open Collaboration." It continues the parent company’s robust IP protection, project management mechanisms, and comprehensive quality management system. Leveraging the core team's successful experience in advancing gene and cell therapy products from clinical trials to market approval, the company provides high-quality and efficient services to global clients, ensuring that effective medicines benefit the public sooner.